Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lysine (K)-specific demethylase 4E | Starlite/ChEMBL | No references |
Homo sapiens | thyroid hormone receptor, beta | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | muscleblind-like splicing regulator 1 | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Brugia malayi | photoreceptor-specific nuclear receptor | thyroid hormone receptor, beta | 461 aa | 414 aa | 24.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0071 | 0.2014 | 0.2283 |
Echinococcus multilocularis | lysine specific demethylase 5A | 0.0071 | 0.2014 | 0.2014 |
Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.0071 | 0.2014 | 0.2014 |
Echinococcus granulosus | lysine specific demethylase 5A | 0.0071 | 0.2014 | 0.2014 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0152 | 0.7929 | 0.899 |
Echinococcus multilocularis | muscleblind protein | 0.018 | 1 | 1 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0152 | 0.7929 | 0.7929 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0 | 0.5 |
Echinococcus granulosus | muscleblind protein | 0.018 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0 | 0.5 |
Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.0071 | 0.2014 | 0.2014 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0071 | 0.2014 | 0.2283 |
Schistosoma mansoni | jumonji domain containing protein | 0.0071 | 0.2014 | 0.2283 |
Brugia malayi | jmjC domain containing protein | 0.0071 | 0.2014 | 0.2014 |
Brugia malayi | jmjC domain containing protein | 0.0071 | 0.2014 | 0.2014 |
Schistosoma mansoni | thyroid hormone receptor | 0.0164 | 0.882 | 1 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0164 | 0.882 | 0.882 |
Schistosoma mansoni | thyroid hormone receptor | 0.0164 | 0.882 | 1 |
Echinococcus multilocularis | muscleblind protein 1 | 0.018 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0152 | 0.7929 | 0.7929 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | 0.7943 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 4.1475 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 4.4668 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.5821 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction. (Class of assay: confirmatory) [Related pubchem assays: 2698 (Summary assay.)] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 44.5625 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia. (Class of assay: confirmatory) [Related pubchem assays: 2472, 2464 ] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.